**High performance. Delivered.**

**KEY FINDING 1**
Investors continue to reward new science.

- The Pipeline Replacement Revenue Ratio has shifted majorly over the past 15 years, indicating a significant drop in the number of NMEs approved across the period.
- Between 2007 and 2011, the number of new molecules dropped to a historical low.
- In 2015, the industry saw mixed results with 38 NMEs approved, 6% above the S&P500 index.

**KEY FINDING 2**
Growth has returned and is forecast to accelerate while margins have improved— but growth continues to be polarized at a company level.

- Six companies are outperforming their peers, with $50 billion in aggregate global revenue, representing nearly half of the global pharmaceutical market by net sales.
- These High Performers for the first time managed to see positive growth in key metrics like top-line revenue, R&D productivity, and profitability, while margins have improved.
- These High Performers are also growing faster than the rest of the global industry.

**KEY FINDING 3**
Affordability and market access will challenge new science as a growth driver.

- The average proportion of new drug launches accessible to patients fell from 9.5 percentage points in 2011 through 2013.
- In 2015, the industry saw mixed results with 38 NMEs approved.
- Investors continue to reward new science as a growth driver.

**KEY FINDING 4**
High Performers will increasingly combine breakthrough medical science with clearly demonstrated outcomes for patients and healthcare systems.

- M&A and collaboration will continue to drive deal volumes.
- Investors continue to reward new science as a growth driver.

---

**About Accenture’s Biopharma- ceutical High Performance Business Study**

Accenture’s study of the biopharmaceutical industry is in its 11th year and has analyzed the long-term performance of “pure-play” pharmaceutical companies in the world over an 8-year period. Collectively these companies had $423 billion in aggregate global revenue, representing nearly half of the global pharmaceutical market by net sales.

**Visit Our Blog**

www.accenture.com/lifesciencesblog

---

**Stay Connected**

- [Facebook](https://www.facebook.com/Accenture)
- [LinkedIn](https://www.linkedin.com/company/Accenture)
- [Twitter](https://twitter.com/AccentureLifSci)
- [Instagram](https://www.instagram.com/Accenture)
- [YouTube](https://www.youtube.com/channel/UCjzqpo6UPlGlXKqbe4Q16tA)

---

**Visit Our Blog**

www.accenture.com/lifesciencesblog